In this study, we investigated the potential use of circulating activated TPH cells and activated CD8 T cells, both expressing PD1 and CD38, to look for residual disease activity of AIH and predict relapse after IS treatment withdrawal. This evidence concerns the gene CD38 and autoimmune hepatitis.